{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:29Z","timestamp":1792787309636,"version":"4.5.0"},"reference-count":32,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"UOEH Grant for Advanced Research","award":["19K17919"],"award-info":[{"award-number":["19K17919"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Education, Culture, Sports, Science and Technology of Japan","id":[{"id":"https:\/\/ror.org\/048rj2z13","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Health, Labour and Welfare of Japan","id":[{"id":"https:\/\/ror.org\/03mwa7s65","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,9,13]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the clinical outcomes and explore longitudinal peripheral blood immunophenotypic changes associated with rituximab (RTX)-based, mycophenolate mofetil (MMF)-based or intravenous cyclophosphamide (IVCY)-based treatment strategies for patients with systemic lupus erythematosus (SLE) and active lupus nephritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed patients with SLE and active lupus nephritis enrolled in the LOOPS registry who received single-agent induction therapy with RTX, MMF or IVCY in addition to glucocorticoids (GCs). The co-primary endpoints were the achievement rates of complete renal response (CRR) and urinary protein-to-creatinine ratio &lt;0.7 g\/gCr at week 52. Secondary endpoints included renal function, proteinuria, disease activity, relapse rate and safety. Peripheral blood immune cell subsets were assessed by multicolour flow cytometry before and after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At week 52, no significant differences were observed in CRR rates or improvement in proteinuria among the groups. Changes in estimated glomerular filtration rate, disease activity measures and concomitant GC dose also did not differ significantly. Exploratory within-strategy analyses showed reduced B-cell subset proportions with RTX and broader reductions, including in activated T cells, with MMF and IVCY. However, treatment strategy-by-time interaction was not significant, providing no evidence of between-strategy differences in longitudinal changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The 52-week clinical effectiveness of the RTX-based, MMF-based and IVCY-based strategies for active lupus nephritis did not differ significantly. Different within-strategy immunophenotypic patterns were observed, but between-strategy differences were not confirmed. Comprehensive immunophenotyping may help characterise immune dynamics and support future response stratification and precision medicine for lupus nephritis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2026-007370","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:30:23Z","timestamp":1790343023000},"page":"e007370","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and immunological outcomes of rituximab-based, mycophenolate mofetil-based and cyclophosphamide-based treatment strategies for systemic lupus erythematosus with active kidney involvement from LOOPS registry"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0212-172X","authenticated-orcid":false,"given":"Masanobu","family":"Ueno","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippei","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"},{"name":"Department of Molecular Targeted Therapeutics, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3022-1317","authenticated-orcid":false,"given":"Hiroaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9693-9263","authenticated-orcid":false,"given":"Satoshi","family":"Kubo","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-3881","authenticated-orcid":false,"given":"Yusuke","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Todoroki","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-9356","authenticated-orcid":false,"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-6595","authenticated-orcid":false,"given":"Ryuichiro","family":"Kanda","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6220-1233","authenticated-orcid":false,"given":"Hidenori","family":"Sakai","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8466-0334","authenticated-orcid":false,"given":"Katsuhide","family":"Kusaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"},{"name":"Department of Molecular Targeted Therapeutics, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2209-8454","authenticated-orcid":false,"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"},{"name":"Department of Molecular Targeted Therapeutics, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2026092506300594000_12.3.e007370.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218272"},{"key":"2026092506300594000_12.3.e007370.2","doi-asserted-by":"crossref","first-page":"101814","DOI":"10.1016\/j.berh.2022.101814","article-title":"Systemic lupus erythematosus","volume":"36","author":"Tanaka","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2026092506300594000_12.3.e007370.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2026092506300594000_12.3.e007370.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.09.007"},{"key":"2026092506300594000_12.3.e007370.5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108455108"},{"key":"2026092506300594000_12.3.e007370.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"2026092506300594000_12.3.e007370.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410965"},{"key":"2026092506300594000_12.3.e007370.8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/mr\/roac007","article-title":"Rituximab in the real-world treatment of lupus nephritis: a retrospective cohort study in Japan","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026092506300594000_12.3.e007370.9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/14397595.2015.1060665","article-title":"Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy","volume":"26","author":"Tanaka","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2026092506300594000_12.3.e007370.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057885"},{"key":"2026092506300594000_12.3.e007370.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201317"},{"key":"2026092506300594000_12.3.e007370.12","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.40180","article-title":"Peripheral immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients","volume":"69","author":"Kubo","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026092506300594000_12.3.e007370.13","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2026092506300594000_12.3.e007370.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"2026092506300594000_12.3.e007370.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819"},{"key":"2026092506300594000_12.3.e007370.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu343"},{"key":"2026092506300594000_12.3.e007370.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.023"},{"key":"2026092506300594000_12.3.e007370.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180"},{"key":"2026092506300594000_12.3.e007370.19","first-page":"377","article-title":"Accurately describing changes in disease activity in Systemic Lupus Erythematosus","volume":"27","author":"Gladman","year":"2000","journal-title":"J Rheumatol"},{"key":"2026092506300594000_12.3.e007370.20","doi-asserted-by":"publisher","DOI":"10.1038\/nri3158"},{"key":"2026092506300594000_12.3.e007370.21","doi-asserted-by":"crossref","unstructured":"Ueno M , Miyagawa I , Miyazaki Y , et al . Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes. Arthritis Res Ther 2022;24. doi:10.1186\/s13075-022-02934-3","DOI":"10.1186\/s13075-022-02934-3"},{"key":"2026092506300594000_12.3.e007370.22","doi-asserted-by":"crossref","first-page":"934937","DOI":"10.3389\/fmed.2022.934937","article-title":"Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: one-year follow-up outcomes","volume":"9","author":"Miyagawa","year":"2022","journal-title":"Front Med"},{"key":"2026092506300594000_12.3.e007370.23","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004567","article-title":"Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus","volume":"10","author":"Ueno","year":"2024","journal-title":"RMD Open"},{"key":"2026092506300594000_12.3.e007370.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224537"},{"key":"2026092506300594000_12.3.e007370.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"2026092506300594000_12.3.e007370.26","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/1756-185X.13387","article-title":"Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus","volume":"22","author":"Miyagawa","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2026092506300594000_12.3.e007370.27","doi-asserted-by":"crossref","DOI":"10.1186\/ar3042","article-title":"Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients","volume":"12","author":"Rodr\u00edguez-Bayona","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2026092506300594000_12.3.e007370.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.08.015"},{"key":"2026092506300594000_12.3.e007370.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.30466"},{"key":"2026092506300594000_12.3.e007370.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.20592"},{"key":"2026092506300594000_12.3.e007370.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725"},{"key":"2026092506300594000_12.3.e007370.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01126-1"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-007370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:30:27Z","timestamp":1790343027000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-007370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2026-007370"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-007370","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}